Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners HSA Plus Formulary Coverage Update …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealthPartnersPolicy N/A

    HSA Plus 2026 Formulary (Drug List)

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the HealthPartners HSA Plus 2026 formulary listing covered medications, tier assignments, and special program flags (e.g., PA, ST, QL) that govern pharmacy coverage and prior authorization/limit requirements for members and providers.

    Policy Summary
    PayerHealthPartners
    PolicyHSA Plus 2026 Formulary (Drug List)
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateApr 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (PA) from HealthPartners when a product's Requirements / Limits field lists PA before dispensing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-04-01Formulary effective
    Tiers 1–7+NFTier structure
    PA, ST, QLCommon controls
    Specialty pharmacySpecialty handling
    multiplePA present

    Coverage and Table Controls

    Coverage determined by table entries

    Coverage and utilization controls are determined by each formulary table row. The product's tier and any listed Requirements / Limits (for example PA, OP, QL, S) must be satisfied for coverage.

    Formulary-based coverage logic: Coverage is determined by the product entry: formulary tier (e.g., 3, NF, 4) and any listed Requirements / Limits such as PA (prior authorization), OP (opioid program), S (specialty) and QL (quantity limit) must be met for coverage.

    Follow the specific product row in the formulary table for exact authorization, specialty, and quantity rules.

    threshold":"","note":"Follow specialty-site rules (e.g., specialty pharmacy, infusion center) indicated on the product row.","children":[]}]}]

    General coverage controls (table-level)

    Coverage and utilization management is product- and formulation-specific as indicated in the table; common controls include:

    Policy Summary
    PayerHealthPartners
    PolicyHSA Plus 2026 Formulary (Drug List)
    Policy CodePolicy N/A
    Change TypeAdministrative — no material clinical changes
    Effective DateApr 1, 2026
    Next Review DateJul 1, 2026
    Key ActionObtain prior authorization (PA) from HealthPartners when a product's Requirements / Limits field lists PA before dispensing.
    SourceLink
    On This Page
    Coverage and Table ControlsFormulary Entries and Code TablesPrior Authorization, Step Therapy, Documentation and RisksPolicy Background and RationaleAbbreviations and Program FlagsStep Therapy Indicators and ApplicationsQuantity Limits by ProductSpecialty Pharmacy and Infusion Requirements
    Common payer controls:
    PA indicated for numerous specialty and high-cost products; QL applies to many formulations with explicit numeric limits per day or per 30 days; S denotes specialty program management or site-specific handling.

    Refer to the individual line item for the exact tier, PA, S and QL values on the formulary table.

    Operational implications: Failure to obtain required PA or to comply with QL/S requirements may result in denial or noncoverage of the drug claim.

    Providers should include diagnosis, previous therapies tried, and other supporting documentation when requesting PA or QL overrides.

    Quantity-limit specifics (examples from table): Representative QL entries include ARIXTRA syringes with QL (24/15/12/18 per 30 days) and ELIQUIS start pack QL (74 per 30 days); many oral and specialty agents list per-day or per-fill limits.

    Exact QL values are shown on each formulation line in the table and govern dispensing and approvals.

    Certain product lines in the formulary excerpt are designated NF (Non‑Formulary) and, where shown, are paired with utilization controls such as PA (prior authorization) or numeric QL (quantity limits). Examples in this fragment include ANCOBON (listed as NF; PA) and several antifungal liquid or specialty formulations (e.g., itraconazole solution, SPORANOX 100 mg, VFEND oral suspension) that are flagged NF and require PA per the table entries. These NF designations imply restricted coverage unless the listed requirements/limits are satisfied.

    Within the provided excerpts there are no standalone clinical exclusion statements tied to diagnoses or patient populations; instead the table uses formulary flags such as NF and constraint codes (for example PA, OP, and explicit QL values) to indicate where coverage is limited or controlled. The presence of NF entries in the drug rows therefore functions as an operational restriction rather than an explicit clinical exclusion in these fragments.

    The excerpt does not include any discrete 'not medically necessary' condition lists. Coverage limitations in these fragments are expressed through formulary status and utilization codes (e.g., NF, PA, QL), not by enumerating procedures or diagnoses considered not medically necessary.

    Formulary Entries and Code Tables

    Stimulant ER / Biphasic Capsulesmixed
    METADATE CD ORAL CAPSULEER BIPHASIC 30-70 10 MG, 20 MG, 30 MG — Drug Tier = NF; Requirements / Limits = PA; QL (2 per 1 day)
    METADATE CD ORAL CAPSULEER BIPHASIC 30-70 40 MG, 50 MG, 60 MG — Drug Tier = NF; Requirements / Limits = PA; QL (1 per 1 day)
    methylphenidate hcl oral capsule, er biphasic 30-7010 mg, 20 mg, 30 mg — Drug Tier = 3; Requirements / Limits = QL (2 per 1 day)
    methylphenidate hcl oral capsule, er biphasic 30-7040 mg, 50 mg, 60 mg — Drug Tier = 3; Requirements / Limits = QL (1 per 1 day)
    Direct oral anticoagulants (DOACs)mixed
    ELIQUIS ORAL TABLET 5 MGDrug Tier = 3; Requirements / Limits = QL (74 per 30 days)
    ELIQUIS ORAL TABLET 2.5 MGDrug Tier = 3; Requirements / Limits = QL (2 per 1 day)
    ELIQUIS DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 5 MG (74 TABS)Requirements / Limits = QL (74 per 30 days)
    Coagulation factor products — Intravenous recon solutionsmixedCovered
    ELOCTATE INTRAVENOUS RECON SOLNAvailable units: 1,000 UNIT, 1,500 UNIT, 2,000 UNIT, 250 UNIT, 3,000 UNIT, 4,000 UNIT, 5,000 UNIT, 500 UNIT, 6,000 UNIT, 750 UNIT — Drug Tier = 6; Requirements / Limits = PA; S
    ADVATE INTRAVENOUS RECON SOLNUnits include 250, 500, 1,000, 1,500, 2,000, 3,000, 4,000 UNIT — Requirements / Limits = PA; S
    ALPHANATE INTRAVENOUS RECON SOLN1,000 (400 VWF) UNIT/10 ML, 1,500 (600 VWF) UNIT/10 ML, 2,000 (800 VWF) UNIT/10 ML, 250 (100 VWF) UNIT/5 ML, 500 (200 VWF) UNIT/5 ML — Requirements / Limits = PA; S
    Specialty injectables & subcutaneous agentsmixed
    HEMLIBRA SUBCUTANEOUS SOLUTIONStrengths: 105 MG/0.7 ML, 12 MG/0.4 ML, 150 MG/ML, 30 MG/ML, 300 MG/2 ML (150 MG/ML), 60 MG/0.4 ML — Drug Tier = 6; Requirements / Limits = PA; S
    FRAGMIN SUBCUTANEOUS SYRINGEMultiple anti-Xa unit strengths — Requirements / Limits = QL (varies)
    JIVI INTRAVENOUS RECON SOLNUnits: 1,000, 2,000, 3,000, 4,000, 500 UNIT — Requirements / Limits = PA; S
    Quantity limit code examplesmixed
    ARIXTRA SUBCUTANEOUS SYRINGEMultiple strengths with QL (12-24 per 30 days depending on strength)
    ELIQUIS DVT-PE TREAT 30D STARTQL (74 per 30 days)
    Formulary status and requirement flags summarymixed
    PAPrior Authorization required (examples: METADATE CD, ELOCTATE, HEMLIBRA)
    QLQuantity limit applied (examples: METADATE CD, ELIQUIS, ARIXTRA)
    SSpecialty distribution (examples: ELOCTATE, HEMLIBRA)
    NFNon-formulary tier designation (examples: METADATE CD entries listed as NF for certain strengths)
    Representative stimulant ER examplesmixed
    METADATE CD ORAL CAPSULE, ER BIPHASIC 30-7010 MG, 20 MG, 30 MG — NF; PA; QL (2 per 1 day)
    METADATE CD ORAL CAPSULE, ER BIPHASIC 30-7040 MG, 50 MG, 60 MG — NF; PA; QL (1 per 1 day)

    Prior Authorization, Step Therapy, Documentation and Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization (PA) is commonly required across the drug list. When a product is marked with PA (or with combined flags such as PA; S; ONC; TD) providers must request prior authorization before the plan will cover the medicine. Failure to obtain required PA may result in denial or non-coverage.

    • PA = Prior Authorization Required
    • Many oncology and specialty agents are additionally flagged ONC, S and/or TD and require PA to establish medical necessity
    • PA-marked oral antiviral and anti-infective formulations (e.g., PAXLOVID, PREVYMIS) may also have quantity limits (QL) and require PA
    Prior Authorization

    PA, Specialty and Quantity‑Limit Combinations

    Some medicines on the list combine multiple program flags (PA; QL; S; ONC; TD). These combinations indicate the product is managed under specialty or oncology programs and that both PA and adherence to quantity limits must be met. Examples include numerous oral oncology agents and specialty injectables.

    • PA + ONC + S + QL examples: BOSULIF, CALQUENCE, everolimus (antineoplastic)
    • PA + S examples: many specialty injectables and high‑cost oral specialty products (see oncology/specialty clusters)
    • PA + QL examples: many antiviral/antibiotic oral formulations (e.g., PAXLOVID QL per day limits)
    Step Therapy

    Step Therapy Requirement

    Step therapy (ST) applies for medicines where the plan requires trials of one or more alternatives before covering the requested product. Items marked ST must follow the plan’s step‑therapy sequencing and require provider attestation or prior approval if steps have not been met.

    • ST = Step Therapy Required
    • Examples where ST is shown in the table: TRINTELLIX (ST), zolpidem XR (ST)
    • Products marked S may also be managed through specialty programs that include step requirements
    Documentation Required

    Quantity Limit Documentation and Overrides

    Quantity limits (QL) are enforced per fill or per time period. Requests that exceed the listed QL are subject to medical necessity review and may be denied if supporting documentation is not provided.

    • QL examples: PAXLOVID (QL per 1 day), ARIKAYCE (QL per 30 days), numerous antiseizure and migraine products have QLs
    • Exceeding QL may trigger a PA review and possible denial
    • When requesting QL overrides include diagnosis, prior therapies tried, and prior use within QL
    Prior Authorization

    Specialty Injectable Products — PA and Site‑of‑Care Considerations

    Specialty injectables and high‑cost infusion products commonly carry PA and S flags and may require site‑of‑care or infusion‑specific handling. Providers should obtain PA and include documentation to meet specialty program requirements to avoid coverage delays.

    • Examples: many injectable biologics and clotting‑factor products marked PA; S (e.g., BENEFIX, ELOCTATE, HEMLIBRA)
    • Infusion or specialty pharmacy management may be required for PA approval
    Documentation Required

    Supporting Clinical Documentation Required for PA / QL / Specialty (S) Items

    Documentation expectations: PA requests and quantity‑limit override requests must include product name/strength, requested quantity, diagnosis, dosing details, prior treatment history (including dates and outcomes), and any relevant clinical test results. For products with combined flags (PA; S; QL) include specialty‑program documentation as indicated.

    • Required claim details: product, strength, quantity and dosing must match the formulary entry
    • Supporting documentation: diagnosis, prior use of requested product within QL, alternatives tried, and clinical rationale
    • For PA+S items, include specialty pharmacy enrollment or justification as required

    Policy Background and Rationale

    Specialty medications in the formulary are managed differently from routine retail drugs: they are typically high‑cost, used for chronic or complex diseases, and require additional handling. The table indicates that specialty medicines must be filled at a specialty pharmacy, and products marked with specialty/site flags (for example S or ONC) may require dispensing or administration through a specialty pharmacy or infusion center per the payer rules.

    Abbreviations and Program Flags

    inv-88: Specialty Medicine definition
    DefinitionSpecialty medicines are usually prescribed by specialists for chronic or complex diseases, are often high-cost, require more management, and must be filled at a specialty pharmacy.
    Benefit noteSpecialty medicines may be covered under a different benefit than non-specialty medicines and checking member benefits is advised.
    inv-89: PA / ST / QL / AL / SC / OP / TD / ONC
    PAPrior Authorization Required
    STStep Therapy Required
    QLQuantity Limit
    AL / SC / OP / TD / ONCAge Limit / Smoking Cessation / Opioid Program / Trial Drug / Oncology Benefit (table abbreviations)
    inv-90: PA definition
    PA (Prior Authorization)Annotation indicating an authorization is required before coverage
    ContextUsed widely for specialty, high-cost, or monitored therapies as shown in the formulary table
    inv-91: QL definition
    QL (Quantity Limit)Annotation indicating the maximum quantity allowed per specified time period (e.g., '8 per 1 day', '180 Per fill')
    FormatShown as 'QL (n per X)' or numeric per fill/day/30 days in the table
    inv-92: S definition
    SSpecial requirement or specialty designation indicating specialty handling or program involvement
    UseAppears alongside PA and QL for certain products (e.g., specialty injectables, oncology agents)
    inv-93: ACA
    ACAAnnotation present in the table; explicit definition not provided in this fragment
    NoteAppears with some products (see table) — refer to full legend at start of table for exact meaning
    inv-94: PA (duplicate cluster)
    PAPrior Authorization — coverage control noted in the Requirements / Limits column indicating authorization is required before coverage
    RepetitionPA appears repeatedly across specialty and oncology listings in the table
    inv-95: QL (duplicate cluster)
    QL (examples)Quantity Limit — restriction on units per fill or time period (e.g., '10 Per fill', '5 per 1 day')
    Provider impactClaims exceeding QL may be denied without supporting documentation
    inv-96: ONC / TD / S / AL
    ONCOncology designation (oncology medicines often require specialty handling and PA)
    TDTreatment designation — additional program flag used in table
    inv-97: Prior Authorization
    Prior Authorization (short)PA — providers must request approval before coverage
    inv-98: Oncology designation
    ONC (oncology)ONC shorthand indicates oncology benefit/handling for listed agents
    inv-99: Quantity Limit example
    Quantity Limit exampleQL (21 per 28 days) — example format shown in table
    inv-100: Prior Authorization (chunk 90)
    Prior Authorization (chunk 90)PA — listed as a requirement in the table
    inv-101: QL (n per X)
    QL (generic)QL (n per X) — generic quantity-limit notation used across the table
    inv-102: Specialty designation S
    S (specialty)S indicates specialty designation or program involvement
    inv-103: Prior Authorization
    PA (repeat)PA — prior authorization required as shown next to many products
    inv-104: Quantity Limit
    QL (repeat)QL — quantity limit per day/28/30 days or per fill as listed
    inv-105: Specialty drug designation S
    S (specialty drug designation)S denotes specialty handling and often pairs with PA/QL for certain agents
    inv-106: NF
    NFNon-formulary or specific tier designation used in the table (NF)
    inv-107: PA
    PA (duplicate)Prior Authorization — repeated table abbreviation
    inv-108: QL
    QL (duplicate)Quantity Limit — repeated table abbreviation
    inv-109: S
    S (duplicate)Specialty/step-related requirement indicator ('S')
    inv-110: Drug Tier / NF
    Drug Tier / NFTable uses numeric tiers and 'NF' to indicate formulary tiering
    inv-111: PA duplicate
    PA (table header examples)PA indicated in Requirements / Limits column — prior authorization required
    QL (table header examples)QL shown as numeric per time period (e.g., per day, per fill)
    OPOperational/override flag appearing with some opioid entries
    inv-112: QL duplicate
    QL (duplicate)Quantity Limit — maximum units per specified time period (per fill/day)
    inv-113: OP
    OP (operational/override)Operational/override flag used in some table entries (appears with QL/PA)
    inv-114: PA duplicate cluster
    PA (cluster)Prior Authorization — appears across multiple clusters indicating PA requirement
    inv-115: QL duplicate cluster
    QL (cluster)Quantity Limit examples and enforcement (per day/per fill) — listed for many products
    inv-116: Drug Tier
    Drug Tier exampleFormulary tier assignments shown numerically (1–7) and NF
    inv-117: OP
    OP (single)Opioid protection or plan-specific flag appears in some entries
    inv-118: PA duplicate cluster
    PA (cluster 198/211)Prior Authorization — listed for many products in these chunks
    inv-119: QL duplicate cluster
    QL (cluster 198/217)Quantity Limit — maximum allowed quantity per time unit (examples shown)
    inv-120: ST
    ST (Step Therapy)When ST appears, members must try specified first-line medications before coverage at lowest cost tier; provider must request approval otherwise
    inv-121: S / TD
    S / TDS = Specialty; TD = Treatment designation — program flags used in table header
    inv-122: Table abbreviations summary
    Table abbreviations summary'PA' = prior authorization; 'S' = specialty; 'QL' = quantity limit; 'ST' = step therapy (legend referenced at table start)

    Step Therapy Indicators and Applications

    Drug list flagMeaning / Plan action
    ST
    Indicates step therapy applies; member must try required first-line medication(s) before the listed product will be covered at the lowest copay/coinsurance. Provider must obtain approval if steps not met.
    Table annotationImplication for coverage
    PA; S
    Product requires prior authorization (PA) and is managed as a specialty item (S); supporting documentation and specialty pharmacy/site requirements apply before coverage.
    Program flagsManagement pathway
    ONC / TD / S
    Oncology (ONC), trial/ treatment designation (TD), and specialty (S) flags denote oncology/specialty pathway management; PA, QL and specialty handling commonly apply.
    Example productTable notation / action
    Carbidopa-levodopa extended release
    Listed in formulary lines; some extended-release carbidopa-levodopa products are marked 'ST', indicating step therapy applies per table notation.
    ProductRequirements / Limits
    INGREZZA initiation pack
    Requirements / Limits = PA; S; QL (28 per 273 days) — initiation pack and other INGREZZA listings show 'S' indicating specialty/step-related controls and prior authorization.
    ObservationExplanation
    No explicit multi-step sequences provided
    The formulary table uses 'ST' where step therapy applies, but detailed multi-step sequencing is not listed in the provided excerpts; many products instead show PA and QL controls.
    Product / flagAction / note
    GEODON (as listed)
    Includes 'AL (Min 7 Years)' age-limit flag in Requirements / Limits — indicates age-based authorization criteria apply (AL).
    ProductTable notation
    TRINTELLIX oral tablet
    Requirements / Limits = ST; QL (1 per 1 day) — Trintellix is specifically marked 'ST' indicating step therapy applies for this agent.
    ProductFormulary flags
    Zolpidem oral tablet, extended-release multiphase
    Requirements / Limits = ST; QL (1 per 1 day) — listed with 'ST', indicating step therapy requirement for this extended-release zolpidem formulation.
    Product group / exampleTable annotations / coverage impact
    Oral anticoagulant formulations (examples: ELIQUIS, XARELTO)
    Selected formulations show QL and some show PA (e.g., ELIQUIS QL entries; XARELTO examples) — PA plus QL or specialty flags on oral anticoagulants indicate additional management and possible step/coverage checks per table entries.

    Quantity Limits by Product

    inv-133: nystatin oral suspension 100,000 unit/ml
    Nystatin oral suspension 100,000 unit/mlQL: 480 per fill
    inv-134: VIVJOA ORAL CAPSULE 150 MG
    VIVJOA oral capsule 150 mgQL: 18 per 84 days
    inv-135: EDURANT PED ORAL TABLET FOR SUSPENSION 2.5 MG
    EDURANT PED oral tablet for suspension 2.5 mgQL: 6 per 1 day
    inv-136: LAGEVRIO (EUA) ORAL CAPSULE 200 MG
    LAGEVRIO (EUA) oral capsule 200 mgQL: 8 per 1 day
    inv-137: PAXLOVID ORAL TABLETS
    PAXLOVID oral tablets (dose packs)QL: 4 or 6 per 1 day depending on dose pack
    inv-138: ALINIA ORAL SUSPENSION
    ALINIA oral suspension for reconstitution 100 mg/5 mlQL: 180 per fill
    inv-139: ARIKAYCE inhalation suspension
    ARIKAYCE inhalation suspension for nebulization 590 mg/8.4 mlQL: 252 per 30 days
    inv-140: TEMBEXA ORAL SUSPENSION
    TEMBEXA oral suspension 10 mg/mlQL: 65 per 8 days
    inv-141: ORLYNVAH ORAL TABLET
    ORLYNVAH oral tablet 500 mgQL: 10 per fill
    inv-142: STROMECTOL ORAL TABLET 3 MG
    STROMECTOL oral tablet 3 mgQL: 40 per fill
    inv-143: TOBI inhalation solution
    TOBI inhalation solution 300 mg/5 mlQL: 5 per 1 day
    inv-144: CALQUENCE oral tablet 100 mg
    CALQUENCE oral tablet 100 mgQL: 2 per 1 day
    inv-145: IBRANCE
    IBRANCEQL: 21 per 28 days
    inv-146: KISQALI
    KISQALIQL: 21 per 28 days
    inv-147: nilotinib D-tartrate
    Nilotinib D-tartrateQL: 4 per 1 day
    inv-148: PEMAZYRE oral tablet
    PEMAZYRE oral tabletQL: 14 per 21 days
    inv-149: PIQRAY oral tablet
    PIQRAY oral tabletQL: 1-2 per 1 day depending on dosing line
    inv-150: POMALYST
    POMALYST (pomalidomide)QL: 21 per 28 days
    inv-151: REVLIMID
    REVLIMID oral capsule (20/25 mg line)QL: 21 per 28 days
    inv-152: ROZLYTREK
    ROZLYTREK oral capsule 200 mgQL: 3 per 1 day
    inv-153: VENCLEXTA 100 mg
    VENCLEXTA oral tablet 100 mgQL: 6 per 1 day
    inv-154: VENCLEXTA 10 mg
    VENCLEXTA oral tablet 10 mgQL: 2 per 1 day
    inv-155: VITRAKVI capsule 25 mg
    VITRAKVI capsule 25 mgQL: 6 per 1 day
    inv-156: VITRAKVI oral solution
    VITRAKVI oral solution 20 mg/mLQL: 10 per 1 day
    inv-157: XROMI oral solution
    XROMI oral solution 100 mg/mLQL: 148 per 30 days
    inv-158: EPIDIOLEX oral solution
    EPIDIOLEX oral solution 100 mg/mLQL: 20 per 1 day
    inv-159: diazepam rectal kit
    Diazepam rectal kitQL: 2 per 30 days
    inv-160: EPIDIOLEX ORAL SOLUTION
    EPIDIOLEX (duplicate)QL: 20 per 1 day
    inv-161: gabapentin oral solution
    Gabapentin oral solution 250 mg/5 mlQL: 72 per 1 day
    inv-162: LYRICA ORAL SOLUTION
    LYRICA oral solution 20 mg/mlQL: 30 per 1 day
    inv-163: perampanel oral suspension
    Perampanel oral suspension 0.5 mg/mlQL: 8 per 1 day
    inv-164: rufinamide oral suspension
    Rufinamide oral suspension 40 mg/mlQL: 80 per 1 day
    inv-165: SYMPAZAN ORAL FILM
    SYMPAZAN oral filmQL: 2 per 1 day
    inv-166: VALTOCO nasal spray
    VALTOCO nasal sprayQL: 5 per fill
    inv-167: VIMPAT oral solution / tablet
    VIMPAT oral solutionQL: 40 per 1 day
    VIMPAT oral tablet 100 mgQL: 4 per 1 day
    inv-169: XCOPRI tablet lines
    XCOPRI tablet linesQL: 1 per 1 day
    inv-170: AIMOVIG / EMGALITY / ELYXYB
    AIMOVIG autoinjector / EMGALITY penQL: 1 per 28 days (each)
    ELYXYB oral solutionQL: 144 per 30 days
    inv-173: AUSTEDO XR TITRATION KT / dalfampridine
    AUSTEDO XR titration kitQL: 1 per day
    Dalfampridine 10 mg ERQL: 2 per day
    inv-175: DAYBUE / RADICAVA
    DAYBUE oral solutionQL: 120 per 1 day
    RADICAVA ORS starter kitQL: 70 per 28 days
    inv-178: WAINUA / fentanyl patch
    WAINUA auto-injectorQL: 0.8 per 30 days
    Fentanyl transdermal patch (selected strengths)QL: 10 per 30 days
    inv-180: hydrocodone-acetaminophen limits
    Hydrocodone-acetaminophen oral solution 7.5-325 mg/15 mlQL: 120 per 1 day
    Hydrocodone-acetaminophen oral tablet (various strengths)QL: 8 per 1 day
    inv-181: opioid/analgesic quantity limits
    Selected opioid/analgesic QLsHydromorphone liquid QL 17 per 1 day; Oxycodone-acetaminophen solution QL 20 per 1 day; Ketorolac injection QL 20 per 30 days; NUCYNTA ER QL 2 per 1 day; Tramadol solution QL 80 per 1 day; Tramadol tablet QL 4 per 1 day
    inv-191: Stimulant quantity limits
    Stimulant/ADHD QL examplesCONCERTA QL 2 per 1 day (18/27/36 mg) or 1 per 1 day (54 mg); Methylphenidate biphasic QL 1-2 per 1 day depending on strength; Dextroamphetamine solution QL 60 per 1 day
    inv-211: Anticoagulant and injectable quantity limits
    Anticoagulant / injectable QLsARIXTRA syringes QL: 24/15/12/18 per 30 days (10/2.5/5/7.5 mg); ELIQUIS start pack QL 74 per 30 days; Enoxaparin QL examples: 48 per 30 days; FRAGMIN QL examples: 114 per 30 days; XARELTO start pack QL 51 per 30 days

    Specialty Pharmacy and Infusion Requirements

    Note
    Note
    Note
    Note